Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.
Bannister
S J
SJ
Beecham Laboratories, Product Development, Bristol, Tennessee.
Houser
V P
VP
Hulse
J D
JD
Kisicki
J C
JC
Rasmussen
J G
JG
D000328:Adult; D000928:Antidepressive Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D002927:Cimetidine / Q000493:pharmacokinetics*; D003975:Diazepam / Q000493:pharmacokinetics*; D004077:Digoxin / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D017374:Paroxetine; D010880:Piperidines / Q000493:pharmacokinetics*; D012702:Serotonin Antagonists / Q000493:pharmacokinetics*; D014859:Warfarin / Q000493:pharmacokinetics*
D000928:Antidepressive Agents; D010880:Piperidines; D012702:Serotonin Antagonists; D017374:Paroxetine; D014859:Warfarin; D004077:Digoxin; D002927:Cimetidine; D003975:Diazepam